Menu
Search

News

Swiss Deep Tech News & Analysis

Stay informed on the Swiss technology landscape. This is your central resource for Deep Tech News, combining key developments from across the ecosystem with original, data-driven analysis from the Deep Tech Nation Foundation. We track and report on significant technological milestones, funding rounds, and research to provide a comprehensive overview for international investors, partners, and researchers.

Curated Newsfeed

See all news

DTN Highlights

See DTN Highlights

  • CHF 10 million seed funding and new board chair for TECregen

    TECregen, a Basel-based biotech company pioneering thymus regeneration, has secured CHF 10 million in a seed financing round led by the Boehringer Ingelheim Venture Fund…

    startupticker.ch

    • TECregen secured CHF 10M seed funding from Boehringer Ingelheim to develop biologics that rejuvenate thymic epithelial cells and restore immune function.
    • The company targets age-related immune decline and thymic damage from chemotherapy, radiation, and infections that impair T-cell production.
    • Dr. Bo Rode Hansen, a biotech executive from Roche and Genevant Sciences, was appointed Chairman to guide TECregen toward clinical development.
    startupticker.ch: CHF 10 million seed funding and new board chair for TECregen

  • TOFWERK joins the Bruker family

    Bruker Corporation has secured an additional 60% equity stake in TOFWERK AG, granting it full ownership of the company. TOFWERK, a specialist in ultra-fast time-of-flight…

    startupticker.ch

    • Bruker acquired an additional 60% stake in TOFWERK, making the Swiss mass spectrometry company a wholly-owned subsidiary.
    • TOFWERK generates approximately $40 million in annual revenue with 130 employees and over 1,000 instruments deployed worldwide.
    • The acquisition expands Bruker's small-molecule MS capabilities for semiconductors, air quality, and food testing.
    startupticker.ch: TOFWERK joins the Bruker family

  • Significant Advances in Pharmaceutical Pipelines for Underserved Diseases

    Oculis, Legacy Healthcare and Neurosterix are advancing their drug pipelines with major clinical milestones. Oculis’ Privosegtor received breakthrough therapy designation from the U.S. Food and…

    startupticker.ch

    • Oculis' Privosegtor received FDA breakthrough designation for optic neuritis, with Phase 2 data showing improved visual acuity and $7B+ U.S.
    • Legacy Healthcare advanced botanical drug Cinainu to Phase 3 for alopecia areata, with plans to expand to atopic dermatitis and psoriasis.
    • Neurosterix initiated Phase 1 trials for NTX-253, an oral M4 modulator for schizophrenia, after raising $65 million Series A in 2024.
    startupticker.ch: Significant Advances in Pharmaceutical Pipelines for Underserved Diseases

  • Switzerland Shines as a Deep Tech Hub at CES 2026

    The first days at the Consumer Electronics Show (CES) have already been exciting for several Swiss startups—Algorized and the KUKA Group unveiled a new robot…

    startupticker.ch

    • 24 Swiss startups showcased innovations at CES 2026 in the swisstech pavilion, from intuitive robots to privacy-focused smartphones.
    • Algorized and KUKA Group unveiled the first robot with intuition that perceives human physiology and adapts in real time.
    • Switzerland ranks #1 globally in innovation, with 60% of venture capital now directed to Deep Tech startups.
    startupticker.ch: Switzerland Shines as a Deep Tech Hub at CES 2026

  • €13.9 million for glucose-monitoring wearable

    Liom, the developer of the world’s first non-invasive glucose-monitoring wearable, has secured additional €13.9 million (CHF 13 million) in its Series A extension round, bringing…

    startupticker.ch

    • Liom raised €13.9M in Series A extension funding, totaling CHF 38M, to launch its non-invasive glucose-monitoring wearable by 2028.
    • Liom's Raman spectroscopy platform needs no needle calibration, outperforms labs 12x, offers 24+ hour battery, and smartwatch form factor.
    • Marc Maurer, former On Running co-CEO, joined Liom's board as investor to guide glucose monitoring tech development and commercialization.
    startupticker.ch: €13.9 million for glucose-monitoring wearable

  • Enlightra raises USD 15 million to tackle the biggest bottleneck in AI infrastructure

    Enlightra, a Swiss-American deeptech startup building chip-scale multiwavelength lasers for next-generation data transmission, announced it has raised a total of $15 million to make data…

    startupticker.ch

    • Enlightra's chip-scale multiwavelength lasers replace copper wiring with optical links in AI data centers, targeting a $24 billion market.
    • The company's multi-color laser technology uses a single integrated source instead of dozens of discrete lasers, reducing power and cost.
    • With $15 million funding, Enlightra plans pilot production in 2027 using standard silicon photonics manufacturing processes.
    startupticker.ch: Enlightra raises USD 15 million to tackle the biggest bottleneck in AI infrastructure

  • Neural Concept closes $100M funding round to scale AI-Native engineering

    Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding…

    startupticker.ch

    • Neural Concept raised $100M in Series C funding led by Goldman Sachs for AI-native engineering workflows.
    • The platform reduces late-stage redesigns by 30-50% and accelerates time to market by up to two years.
    • Neural Concept plans to launch generative CAD in early 2026 and expand partnerships with major tech firms.
    startupticker.ch: Neural Concept closes $100M funding round to scale AI-Native engineering

  • FoRx Therapeutics raises $50 million to advance clinical trials

    In August this year, FoRx Therapeutic initiated its first human trial Phase 1 clinical development of its lead drug candidate, FORX-428,  designed to target and…

    startupticker.ch

    • FoRx Therapeutics raised $50M Series A to advance Phase 1 trials of FORX-428, a DNA Damage Response inhibitor targeting PARG for cancer.
    • FORX-428 treats advanced solid tumors resistant to PARP inhibitors, with initial clinical data expected by mid-2026.
    • Preclinical studies showed FORX-428 demonstrated anti-tumor activity with favorable safety across multiple tumor types in mono and combination settings.
    startupticker.ch: FoRx Therapeutics raises $50 million to advance clinical trials

  • Swiss-US startup HomeBuddy acquired for $190 million

    Established by Schwyz-based SIREN GROUP AG, HomeBuddy is a digital marketplace platform that matches homeowners with the most appropriate home services professional. QuinStreet, a leader…

    startupticker.ch

    • QuinStreet acquired HomeBuddy for $190M ($115M cash, $75M over 4 years) to expand its home services marketplace.
    • HomeBuddy brings 6M monthly visitors and high-intent leads to serve 2,000+ enterprise contractors across 30+ trades.
    • The acquisition adds consumer reach, lead distribution via auction format, and strengthens QuinStreet's lending marketplace.
    startupticker.ch: Swiss-US startup HomeBuddy acquired for $190 million

  • Los Angeles cloud production studio acquires PRODUCER

    PRODUCER.io is a Swiss-based production management platform trusted by with more than 20’000 users, including in-house media departments worldwide. The company has joined the family…

    startupticker.ch

    • CREE8 acquired PRODUCER.io, a Swiss production management platform with 20,000+ users, to build a complete creative ecosystem.
    • PRODUCER is trusted by major brands like Zalando and offers ISO 27001 certification, SSO, and Microsoft Marketplace availability.
    • The combined platform enables creative teams to collaborate across production lifecycle with shared context and AI-ready capabilities.
    startupticker.ch: Los Angeles cloud production studio acquires PRODUCER

  • SK Capital acquires majority stake in Swixx Biopharma at EUR 1.5 billion valuation

    HBM Healthcare Investments, together with the founders and other shareholders such as Mérieux Equity Partners, will sell a majority of their current stake in Swixx…

    startupticker.ch

    • HBM Healthcare Investments sells majority stake in Swixx Biopharma to SK Capital Partners for over EUR 1.5 billion, retaining 25.1%.
    • Swixx Biopharma grew revenues from EUR 40 million in 2017 to expected EUR 1.3 billion in 2026, operating in 45 countries.
    • HBM's EUR 26 million investment in Swixx generated approximately CHF 300 million in added value, over ten times the original.
    startupticker.ch: SK Capital acquires majority stake in Swixx Biopharma at EUR 1.5 billion valuation

  • Swiss delegation warms up for CES 2026 in Las Vegas

    The upcoming year will again kick off with the annual Consumer Electronic Show (CES) in Las Vegas, held on 6-9 January 2026. Close to 150’000…

    startupticker.ch

    • CES 2026 in Las Vegas (January 6-9) features 17 Swiss startups, 12 backed by Innosuisse, at the Swisstech Pavilion.
    • Swiss startups showcase innovations in AR/VR, health tech, batteries, AI diagnostics, and sustainable energy.
    • Participating startups can enter the Global Deep Tech Battle pitch contest; registration closes December 28, 2025.
    startupticker.ch: Swiss delegation warms up for CES 2026 in Las Vegas